BioSpace News Archive

Assay targets monkeypox virus and can deliver results in 90 minutes Company swiftly rolls out product using its automated assay development system “Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics.”

The specialized resource offers patients with rare mutations or fusions in non-small cell lung cancer (NSCLC) and their caregivers access to treatment information, informative webinars, the latest scientific news, and a supportive community.

Revolutionary Apyx Medical Device Used by Top Physicians in the US Now Available to Patients for Nonsurgical Facial Renewal.

Eliassen Group, a strategic consulting company, announced today the appointment of individuals to several crucial roles: Eleanore Doyle as President, Global Head of Life Sciences and Doug Nelson as Chief Financial Officer.

ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea, announced plans for a new 32,219-square-foot facility in Pleasanton, California, USA.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be presenting at the H.C. Wainwright Preclinical Cancer Drug Discovery: Emerging Targets and Modalities virtual conference on June 29, 2022.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine.

Company Also Announces First Licensing Agreement for PBIO with Global BioLife, Inc. for broad based Anti-Viral Fighting Compounds.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $6.5 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock.

IV BioHoldings (IVBH) – a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improve the detection, diagnosis and treatment of disease – has partnered with Sonrai Analytics.